학술논문
Different epidemiology of bloodstream infections in COVID-19 compared to non-COVID-19 critically ill patients: a descriptive analysis of the Eurobact II study
Document Type
Report
Author
Buetti, Niccolò; Tabah, Alexis; Loiodice, Ambre; Ruckly, Stéphane; Aslan, Abdullah Tarik; Montrucchio, Giorgia; Cortegiani, Andrea; Saltoglu, Nese; Kayaaslan, Bircan; Aksoy, Firdevs; Murat, Akova; AkdoÄan, üzlem; Saracoglu, Kemal Tolga; Erdogan, Cem; Leone, Marc; Ferrer, Ricard; Paiva, José-Artur; Hayashi, Yoshiro; Ramanan, Mahesh; Conway Morris, Andrew; Barbier, François; Timsit, Jean-François; Lipman, Jeffrey; Litton, Edward; Palermo, Anna Maria; Yap, Timothy; Eroglu, Ege; Hosokawa, Koji; Yoshida, Hideki; Fujitani, Shigeki; Zand, Farid; Mahmoodpoor, Ata; Tabatabaei, Seyed Mohammad Nasirodin; Elrabi, Omar; Almekhlafi, Ghaleb A.; Vidal, Gabriela; Aparicio, Marta; Alonzo, Irene; Namendys-Silva, Silvio A.; Hermosillo, Mariana; Castillo, Roberto Alejandro; De Bus, Liesbet; De Waele, Jan; Hollevoet, Isabelle; De Schryver, Nicolas; Serck, Nicolas; Kovacevic, Pedja; Zlojutro, Biljana; Ruppe, Etienne; Montravers, Philippe; Dulac, Thierry; Castanera, Jérémy; Massri, Alexandre; Guesdon, Charlotte; Garcon, Pierre; Duprey, Matthieu; Philippart, François; Tran, Marc; Bruel, Cédric; Kalfon, Pierre; Badre, Gaëtan; Demeret, Sophie; Le Guennec, Loïc; Bassetti, Matteo; Giacobbe, Daniele; Sales, Gabriele; Daroui, Ivan; Lodi, Giovanni; Ippolito, Mariachiara; Bellina, Davide; Di Guardo, Andrea; Rocco, Monica; Fiorelli, Silvia; Mikstacki, Adam; Peichota, Mariusz; Pietraszek-Grzywaczewska, Iwona; Póvoa, Pedro; Krystopchuk, Andriy; Teresa, Ana; de Figueiredo, António Manuel Pereira; Botelho, Isabel; Costa, Vasco; Cunha, Rui Pedro; Gritsan, Alexey; Belskiy, Vladislav; Furman, Mikhail; Martinez, Maria; Casares, Vanessa; Arnillas, Maria Pilar Gracia; Bermudez, Rosana Munoz; Ubeda, Alejandro; Salgado, Maria; Maseda, Emilio; De La Rica, Alejandro Suarez; Blasco-Navalpotro, Miguel Angel; Gallego, Alberto Orejas; Prazak, Josef; Pagani, J. L.; Abed-Maillard, S.; Iskit, Arzu Topeli; Mehtap, Selcuk; Ceyhun, SolakoÄlu; Kalem, AyÅe Kaya; Kurt, Ibrahim; Telli, Murat; Ozturk, Barcin; Baykam, Nurcan; Karaali, Ridvan; Koksal, Iftihar; Bilir, Yeliz; Guzeldag, Seda; Ersoz, Gulden; Evik, Guliz; Bayindir, Yasar; Ersoy, Yasemin; Ercole, Ari; Raj, Ashok; Zormpa, Artemis; Tinaslanidis, George; Khade, Reena; Roshdy, Ashraf; Kannan, Santhana; Antrolikar, Supriya; Marsden, Nicholas; Attwood, Ben; Patel, Jamie; Gurjar, Mohan; Dsilva, Carol; Chandran, Jagadish; Sanousi, Bashir El; Saidahmed, Elfayadh; Hamid, Hytham K. S.
Source
Critical Care. October 18, 2022, Vol. 26 Issue 1
Subject
Language
English
ISSN
1364-8535
Abstract
Author(s): Niccolò Buetti[sup.1,2] , Alexis Tabah[sup.3,4,5] , Ambre Loiodice[sup.6] , Stéphane Ruckly[sup.6] , Abdullah Tarik Aslan[sup.7] , Giorgia Montrucchio[sup.8,9] , Andrea Cortegiani[sup.10,11] , Nese Saltoglu[sup.12] , Bircan Kayaaslan[sup.13] , Firdevs [...]
Background The study aimed to describe the epidemiology and outcomes of hospital-acquired bloodstream infections (HABSIs) between COVID-19 and non-COVID-19 critically ill patients. Methods We used data from the Eurobact II study, a prospective observational multicontinental cohort study on HABSI treated in ICU. For the current analysis, we selected centers that included both COVID-19 and non-COVID-19 critically ill patients. We performed descriptive statistics between COVID-19 and non-COVID-19 in terms of patients' characteristics, source of infection and microorganism distribution. We studied the association between COVID-19 status and mortality using multivariable fragility Cox models. Results A total of 53 centers from 19 countries over the 5 continents were eligible. Overall, 829 patients (median age 65 years [IQR 55; 74]; male, n = 538 [64.9%]) were treated for a HABSI. Included patients comprised 252 (30.4%) COVID-19 and 577 (69.6%) non-COVID-19 patients. The time interval between hospital admission and HABSI was similar between both groups. Respiratory sources (40.1 vs. 26.0%, p < 0.0001) and primary HABSI (25.4% vs. 17.2%, p = 0.006) were more frequent in COVID-19 patients. COVID-19 patients had more often enterococcal (20.5% vs. 9%) and Acinetobacter spp. (18.8% vs. 13.6%) HABSIs. Bacteremic COVID-19 patients had an increased mortality hazard ratio (HR) versus non-COVID-19 patients (HR 1.91, 95% CI 1.49-2.45). Conclusions We showed that the epidemiology of HABSI differed between COVID-19 and non-COVID-19 patients. Enterococcal HABSI predominated in COVID-19 patients. COVID-19 patients with HABSI had elevated risk of mortality. Trial registration ClinicalTrials.org number NCT03937245. Registered 3 May 2019. Keywords: Bloodstream infection, ICU-acquired, COVID-19, Enterococcus, Bacteremia
Background The study aimed to describe the epidemiology and outcomes of hospital-acquired bloodstream infections (HABSIs) between COVID-19 and non-COVID-19 critically ill patients. Methods We used data from the Eurobact II study, a prospective observational multicontinental cohort study on HABSI treated in ICU. For the current analysis, we selected centers that included both COVID-19 and non-COVID-19 critically ill patients. We performed descriptive statistics between COVID-19 and non-COVID-19 in terms of patients' characteristics, source of infection and microorganism distribution. We studied the association between COVID-19 status and mortality using multivariable fragility Cox models. Results A total of 53 centers from 19 countries over the 5 continents were eligible. Overall, 829 patients (median age 65 years [IQR 55; 74]; male, n = 538 [64.9%]) were treated for a HABSI. Included patients comprised 252 (30.4%) COVID-19 and 577 (69.6%) non-COVID-19 patients. The time interval between hospital admission and HABSI was similar between both groups. Respiratory sources (40.1 vs. 26.0%, p < 0.0001) and primary HABSI (25.4% vs. 17.2%, p = 0.006) were more frequent in COVID-19 patients. COVID-19 patients had more often enterococcal (20.5% vs. 9%) and Acinetobacter spp. (18.8% vs. 13.6%) HABSIs. Bacteremic COVID-19 patients had an increased mortality hazard ratio (HR) versus non-COVID-19 patients (HR 1.91, 95% CI 1.49-2.45). Conclusions We showed that the epidemiology of HABSI differed between COVID-19 and non-COVID-19 patients. Enterococcal HABSI predominated in COVID-19 patients. COVID-19 patients with HABSI had elevated risk of mortality. Trial registration ClinicalTrials.org number NCT03937245. Registered 3 May 2019. Keywords: Bloodstream infection, ICU-acquired, COVID-19, Enterococcus, Bacteremia